

European Nanomedicine CharacterisationLaboratory

Patrick Boisseau ¹, Matthias Roesslein², Klaus-Michael Weltring³, Simon Bacconier¹, Susanne Bremer-Hoffmann⁴, Fanny Caputo¹, François Rossi⁴, Neill Liptrott⁵, Ruth Schmid⁶, Adriele Prina-Mello⁷, Sven Even Borgos⁶, Andrew Owen⁵, Oliver Panzer⁸, Scott McNeil⁹


¹Commissariat à l'énergie atomique et aux énergies alternatives, ²Eidgenoessische Materialpruefungs- und Forschungsanstalt, ³Gesellschaft für Bioanalytik Münster e. V, ⁴European Commission's Joint Research Centre, ⁵University of Liverpool, ⁶Stiftelsen SINTEF, ⁷Trinity College Dublin, ⁸European Research Services GmbH, ⁹Leidos Biomedical Research, Inc


Selection of promising Med-NPs from R&D community (Academia, RTO, SME, Pharma) Illustration by 8. Mellor. Clinical EUTCL Market Characterisation Characterisation RTO, SME, Pharma) REQUIRED. Clinical EUTCL Market Regulatory agencies

Our Objectives

- To perform and standardize the pre-clinical characterization of nanomaterials intended for medical therapies in Europe
- To accelerate translation of engineered nanoparticles for medicine applications to medicinal products
- To improve quality of data in IMP applications by using recognised and standardised methods
- To support product developer by addressing feedback of decision makers regarding nanospecific properties
- To identify and to characterize critical parameter related to nanomaterial interaction with biological systems







Soon open for business

- Open call for access to be published in March 2016
- Specific for IV route, cancer targeting and organic nanomaterials (including liposomes, lipid nanoparticles, dendrimers, polymeric nanoparticles)
- 2 steps submission process: International expertise/ review and EUNCL experts feedback

Who can apply?

Call for access open to all stakeholders, private and public Free of charge full characterization cascade (if proposal accepted)

Mandatory criteria

- Min 2 batches of product available
- Has demonstrated efficacy in biological system
- Scaling up capacities
- Plan or strategy to transfer the technology to clinics

Exclusion criteria

- In vitro diagnostics technologies and devices
- Project not funded
- Technology/material not compatible with our assay and toolset
- Radioactive solution (except if cold analog is possible)
- Not yet available material

www.euncl.eu is now online, check the site for news and updates!!!

Patrick BOISSEAU

Microtechnologies for Biology and Healthcare Division
Commissariat à l'énergie atomique et aux énergies alternatives
MINATEC Campus | 17 rue des martyrs | F-38054 Grenoble Cedex
Patrick.boisseau@cea.fr

Simon BACCONIER

Clinatec

Commissariat à l'énergie atomique et aux énergies alternatives MINATEC Campus | 17 rue des martyrs | F-38054 Grenoble Cedex Simon.bacconier@cea.fr

